Best printers for Home

Best Mixer Grinder

Best wired Earphones

Best 43 Inch TV in India

Best Wi Fi Routers

Best Home Theatre in India

Smart Watch under 5000

Best Laptops for Education

Best Laptop for Students

10 richest women in India in 2024

<keyword id="6354512" type="General" weightage="100" keywordseo="infosys" source="Orion">Infosys</keyword> on Thursday announced the retirement of <keyword id="1440" type="General" weightage="80" keywordseo="kiran" source="Orion">Kiran</keyword> Mazumdar-Shaw as <keyword id="6390711" type="General" weightage="80" keywordseo="independent" source="Orion">Independent</keyword> Director from its Board, effective March 22, 2023, upon completion of her tenure. Accordingly, the Board has appointed D <keyword id="120337" type="General" weightage="80" keywordseo="sundaram" source="Orion">Sundaram</keyword> as the Lead Independent Director of the Company, effective Thursday based on the recommendation of the 'Nomination and Remuneration Committee'. Sundaram has been on the Board of Infosys since 2017. Sundaram serves on the Audit Committee, Risk Management Committee, <keyword id="16919243" type="General" weightage="50" keywordseo="stakeholders-relationship-committee" source="Orion">Stakeholders Relationship Committee</keyword>, Nomination and Remuneration Committee, and Cybersecurity Risk Sub-Committee. "We profusely thank Kiran for having been such an integral member of the Infosys family, providing valuable guidance and leadership to the Board over the years. I am personally very grateful to her as she has been a tremendous ally and amazing colleague on the Board, ever since I re-joined Infosys in August 2017," chairman of Infosys Nandan Nilekani, said. "We also congratulate Sundaram on being appointed as Lead Independent Director and look forward to his continued insight and steadfast support as Infosys continues its growth and transformation journey," Nilekadded. Kiran Mazumdar-Shaw was appointed to the Infosys' Board as an Independent Director in 2014, and as Lead Independent Director in 2018. She also served as the Chairperson of the 'Nomination &amp; Remuneration Committee' and 'CSR Committee', and as a member of the 'Risk Management and ESG Committees' of the Board. "The Board places on record its appreciation for Ms Shaw's invaluable contribution, guidance, and strategic vision, which has helped the Company build and execute a resilient growth strategy," Infosys said in a release. Kiran Mazumdar-Shaw is the Chairperson and Managing Director of Biocon Limited, a biotechnology company based in Bangalore, India. SEE ALSO: <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/business/news/former-idbi-gm-conspired-with-vijay-mallya-over-short-term-loan-to-kingfisher-airlines-cbi/articleshow/98936880.cms">Former IDBI GM conspired with Vijay Mallya over short term loan to Kingfisher Airlines: CBI</a> <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/finance/banks/news/fm-nirmala-sitharaman-likely-to-meet-psu-banks-heads-on-saturday/articleshow/98936889.cms">FM Nirmala Sitharaman likely to meet PSU banks heads on Saturday</a>

Kiran Mazumdar-Shaw to retire from Infosys board

Global biopharmaceuticals company <keyword id="6358361" type="General" weightage="100" keywordseo="biocon" source="Orion">Biocon</keyword> on Wednesday reported 23 per cent rise in revenue for the first quarter of financial year 2023, at Rs 2,217 crore. "We have had a strong start to the year. At a consolidated level, YoY revenues grew 23 per cent backed by robust growth in both <keyword id="6359687" type="General" weightage="50" keywordseo="biosimilars" source="Orion">Biosimilars</keyword> (29 per cent) and Generics (19 per cent). Core earnings before interest, taxes, depreciation, and amortisation (EBITDA) grew 25 per cent and margin improved to 31 per cent compared to 30 per cent in Q1FY22 and net profit grew 71 per cent to Rs 144 crore. "Our financial performance this quarter includes the impact of annual increments in personnel costs as well as increased input and freight costs, pursuant to pandemic and geopolitical disruptions of global supply chains. "All our three businesses are poised for the next phase of strong and sustainable growth which has been challenged during the two years of the Covid-19 pandemic," <keyword id="14575168" type="General" weightage="50" keywordseo="biocon-and-biocon-biologics-executive" source="Orion">Biocon and Biocon Biologics Executive</keyword> <keyword id="10034873" type="General" weightage="20" keywordseo="chairperson-kiran-mazumdar-shaw" source="Orion">Chairperson Kiran Mazumdar-Shaw</keyword> said. Sales of Glargine in the US, and key biosimilars in emerging markets were the main drivers for <keyword id="14245336" type="General" weightage="50" keywordseo="biocon-biologicals" source="Orion">Biocon Biologicals</keyword>' strong performance. <keyword id="10493627" type="General" weightage="50" keywordseo="biocon-biologics-ltd" source="Orion">Biocon Biologics Ltd</keyword> Managing Director <keyword id="287851" type="General" weightage="50" keywordseo="arun-chandavarkar" source="Orion">Arun Chandavarkar</keyword> said: "Initiation of global clinical trials for two monoclonal antibodies and advancement of our other pipeline assets led to a 120 per cent increase in our research and development investments this quarter. Whilst this impacts EBITDA in the near term, such investments will create a strong portfolio to secure our future growth. "Our strategic alliance with Serum Institute Life Sciences for vaccines and the acquisition of Viatris' global biosimilars business are on track for closure in the second half of this calendar year." SEE ALSO: <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/india/news/reduction-in-rice-cereals-sown-area-worrisome-bank-of-baroda/articleshow/93175801.cms">Reduction in rice, cereals sown area worrisome: Bank of Baroda</a> <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/tech/news/oppo-pad-air-review-sleek-and-stylish-but-short-on-power/articleshow/93165775.cms">Oppo Pad Air review: Sleek and stylish but short on power</a>

Biocon Q1FY23 revenue up 23% at Rs 2,217 cr

<ul><li>Half of the billionaires, including Mukesh Ambani, Radhakishan Damani, Gautam Adani, Cyrus Poonawalla, saw significant gains in their wealth. </li><li>The biggest percentage gainer was 67-year old Kiran Mazumdar-Shaw, Biocon founder and the second richest woman in India. </li><li>While Biocon has joined the race to discover the vaccine, Shaw was not immune to COVID-19. She tested positive in August and recovered in a fortnight. </li></ul>India’s super-rich club of 100 people has added nine new faces and about $88 billion collectively during the coronavirus pandemic — which is assumed to be far worse than the Great Depression. Half of the billionaires, including Mukesh Ambani, Radhakishan Damani, Gautam Adani, Cyrus Poonawalla saw significant gains — taking the collective net worth of 100 billionaires to $517.5 billion, <a href="https://www.forbes.com/sites/naazneenkarmali/2020/10/07/indias-100-richest-2020-collective-net-worth-of-countrys-richest-rose-14-despite-pandemic/#2cf4d5e93da4">Forbes reported. </a> The biggest percentage gainer was 67-year old Kiran Mazumdar-Shaw, Biocon founder and the second richest woman in India. Her wealth has nearly doubled from $2.38 billion in 2019 to $4.6 billion in 2020 — a whopping 93.28% gain among India's 100 richest. She is one of the only five women billionaires in India. <keyword id="55796" type="PERSON" weightage="20" keywordseo="Kiran-Mazumdar-Shaw">Kiran Mazumdar Shaw</keyword> started her Indian-based pharma company about 42 years ago with merely two employees and $500 funds. However, it was not until 2014 that her company became a publicly-traded entity. It touched the $1billion mark on the very day it listed. Over the past decade, Biocon has grown by leaps and bounds to become a $5 billion company. In just the last 12 months, Biocon’s share price has surged 99% from ₹233 in October 2019 to ₹464.70 currently. <div type="image" title="Biocon11" msid="78569590" hostid="261"></div> While her company has joined the race to discover a vaccine to fight the virus, Shaw wasn’t immune to it. On August 16, she tested positive for COVID-19 and recovered 15 days later. Shaw has been vocal about leveraging science to contain the virus. Three months after coronavirus broke out in India, Biocon announced that it would launch biologic drug Itolizumab for the treatment of moderate to severe COVID-19 patients at a price of around ₹8,000 per vial. The pharmaceutical is set to begin the phase-4 trials of the potential drug. Well, Shaw might have gained the most, but Mukesh Ambani’s record gains have left everyone behind. He remains India’s richest man for the 13th year in the running and leads by a large margin. Ambani added $37.3 billion to his fortune, thanks to the trail of investments in Reliance Jio and his retail venture. Jio alone got $20 billion investments from investors like Google, Facebook, and Microsoft. SEE ALSO: <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/business/corporates/news/tcs-beats-accenture-to-become-the-worlds-most-valuable-it-services-company/articleshow/78566487.cms">TCS beats Accenture to become the world’s most valuable IT services company — but this not the first time it has raced ahead</a>

India’s second richest woman nearly doubles her wealth to $4.6 billion during the COVID-19 pandemic

India’s richest women as per Hurun list: Kiran Mazumdar Shaw and Smita Crishna on top

<ul><li>On June 5, Biocon’s Executive <keyword id="9348685" type="PERSON" weightage="20" keywordseo="chairperson-kiran-mazumdar-shaw">Chairperson Kiran Mazumdar Shaw</keyword> was named as <keyword id="9348456" type="UNKNOWN" weightage="20" keywordseo="ey-world-entrepreneur-of-the-year">EY World Entrepreneur of the Year</keyword> 2020. </li><li>With this, she joined Uday Kotak of Kotak Mahindra Bank and Narayana Murthy of Infosys, who were awarded with this honour in 2014 and 2005, respectively. </li><li>She founded the India-based pharma company Biocon with merely two employees and funds worth $500. </li><li>In 2014, Biocon became the first biopharma company to be a publicly-traded entity and the second company to touch the $1 billion mark on the very first day of the listing.</li></ul>In 1978, <keyword id="55796" type="PERSON" weightage="20" keywordseo="Kiran-Mazumdar-Shaw">Kiran Mazumdar Shaw</keyword> founded the India-based pharma company Biocon with merely two employees and funds worth $500. 42 years later, Shaw has been named as <keyword id="9348684" type="UNKNOWN" weightage="20" keywordseo="ey-world-entrepreneur">EY World Entrepreneur</keyword> of the Year 2020. <div type="twitter" handle="EY_EOY" handlename="EY EOY" image="http://pbs.twimg.com/profile_images/877518155282878464/HTnSrpib_normal.jpg" favoritecount="302" retweetcount="123" status="Congratulations to @kiranshaw, Executive Chairperson of India-based @Bioconlimited who is named EY World Entreprene… https://t.co/eYxchprTNh" createdat="1591297093000" id="1268618074879438853"></div> With this, she has joined the likes of Uday Kotak of Kotak Mahindra Bank and Narayana Murthy of Infosys, who were awarded with this honour in 2014 and 2005 respectively. The virtual award ceremony was held on June 5 — and she was chosen from over 46 entrepreneurs from 41 countries. “She has built India's largest biopharmaceutical company on a foundation of compassionate capitalism and putting patient needs before profits,” Chair of the EY World Entrepreneur Of The Year judging panel <a href="https://www.prnewswire.com/in/news-releases/dr-kiran-mazumdar-shaw-from-india-named-ey-world-entrepreneur-of-the-year-tm-2020-883966722.html">said</a>. An aspiring Brewmaster who opened a bio-enzymes company <div type="image" title="eea0f7895182bcc364abaeda35e570da" msid="76208305" hostid="261"></div> Kiran, who graduated from Australia in 1975 wanted to work as a Brewmaster — a person who looks after everything that goes in the process of making a beer. Little did she know, the brewing industry — which is highly male-dominated in India — will not accept a woman in the role. But, that did not stop her. Two years down the line, she started Biocon in a rented house in Bengaluru where they produced the bio enzymes in the garage. A year of struggle and Biocon became the first such company in India that exported enzymes to other countries like the US and Europe. Years later, in 2004, she came up with <keyword id="1829392" type="COMPANY" weightage="20" keywordseo="Biocon-Foundation">Biocon Foundation</keyword> — which aims to provide healthcare and sanitation facilities and diagnosis and treatment of cancer and other non-communicable diseases to weaker sections of the society. Bicon goes public <div type="image" title="06c05f1aefb71a5e6abe2fa9b1bd87fa" msid="76208327" hostid="261"></div> In 2014, Biocon became the first biopharma company to be a publicly-traded entity and the second company to touch the $1 billion mark on the very first day of the listing. Over the years, the bio-enzymes major — which is now one of the prominent biotech giants in Asia — grew multifold to become a <a href="https://www.businessinsider.in/stock-market/news/biocon-share-price-falls-after-earnings-and-mutual-funds-stake-in-the-stock/articleshow/75754048.cms">$5 billion company</a>. Today, Biocon provides healthcare requirements like insulin for diabetes, biosimilars for those fighting cancer, arthritis and other severe diseases. The company reported revenue worth $800 million, as of FY19 and employees more than 11,000 people. In fact, Biocon has created its mark where other pharma giants are struggling and has a presence in over 120 countries. That includes fermentation-based molecules, human insulin, contract research services and more. That may be because of the affordability of the products. In September 2019, Biocon announced the supply of a special kind of insulin to middle income companies on low prices — in fact, less than a third of the current prices. Meanwhile, Shaw has been an angel investor for a lot of startups in the healthcare domain including those in areas like breast cancer screening, chemotherapy and others. In times of the global pandemic While the world is waiting with bated breath for a vaccine to treat coronavirus, Shaw believes that it will take <a href="https://www.businessinsider.in/science/health/news/biocon-chairperson-kiran-mazumdar-shaw-says-indias-covid-19-vaccines-will-enter-clinical-trial-in-9-months/articleshow/75591805.cms">at least nine months for the COVID-19 vaccine to enter clinical trials</a> in India. She also said that there will be multiple waves before the coronavirus curve flattens as community spread remains a key challenge in India. See also: <a href="https://www.businessinsider.in/business/news/mubadala-to-buy-1-85-pc-stake-in-jio-platforms-for-rs-9093-6-cr/articleshow/76205654.cms?upcache=2">Abu Dhabi's Mubadala to buy 1.85% stake in Ambani's Jio Platforms for ₹9093.6 crore</a> <a href="https://www.businessinsider.in/policy/foreign-policy/news/a-former-diplomat-explains-why-four-agreements-will-take-india-and-australia-ties-to-the-next-level/articleshow/76206931.cms">Beyond ‘khichdi’ and ‘samosa’ ⁠— a former diplomat explains why four agreements will take India and Australia ties to the next level</a>

You Searched For "Kiran Mazumdar Shaw" and got 6 results

10 richest women in India in 2024

Ashmita Gupta

Kiran Mazumdar-Shaw to retire from Infosys board

ANI

Biocon Q1FY23 revenue up 23% at Rs 2,217 cr

IANS

India’s second richest woman nearly doubles her wealth to $4.6 billion during the COVID-19 pandemic

Preeti Soni

India’s richest women as per Hurun list: Kiran Mazumdar Shaw and Smita Crishna on top

Rounak Jain

Biocon’s Kiran Mazumdar Shaw, who debuted in the pharma industry with two employees and $500 becomes EY World Entrepreneur of the Year 2020

Prerna Sindwani

Popular Keywords

Buying Guides